Feb 4, 2025
February 2025 ? [New Jersey, United States] ? Axela Biosciences is proud to announce that it has officially obtained CLIA certification, reinforcing its commitment to providing high-quality diagnostic and translational research services for biotech, pharma, and clinical partners.
Following the November 2024 merger of Nanobiotec (PicoImmune) and Emerther, Axela Biosciences has expanded its capabilities to offer comprehensive preclinical bioassays, biomarker discovery, wet lab consumables, and in vitro diagnostic solutions. Achieving CLIA certification now enables Axela to support clinical-grade diagnostic assay development, regulatory-compliant biomarker testing, and sample processing for translational research.
"Securing CLIA certification marks a significant milestone for Axela Biosciences, allowing us to bridge the gap between preclinical research and clinical application," said Harris Zhang, CSO of Axela Biosciences. "This certification underscores our commitment to delivering precise, reproducible, and compliant diagnostic solutions for our clients."
With CLIA-certified capabilities, Axela Biosciences can now offer validated diagnostic assays, advanced molecular and protein-based testing, and regulatory-compliant data for clinical applications. The company remains dedicated to accelerating research in oncology, immunology, neurology, and rare diseases.
For more information on Axela Biosciences' expanded services and CLIA-certified offerings, visit Axelabio.com or contact david.huang@axelabio.com.
Company:
View Axela Biosciences's profile
Links:
